318 related articles for article (PubMed ID: 32296034)
1. PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.
Luszczak S; Kumar C; Sathyadevan VK; Simpson BS; Gately KA; Whitaker HC; Heavey S
Signal Transduct Target Ther; 2020 Jan; 5(1):7. PubMed ID: 32296034
[TBL] [Abstract][Full Text] [Related]
2. Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer.
Luszczak S; Simpson BS; Stopka-Farooqui U; Sathyadevan VK; Echeverria LMC; Kumar C; Costa H; Haider A; Freeman A; Jameson C; Ratynska M; Ben-Salha I; Sridhar A; Shaw G; Kelly JD; Pye H; Gately KA; Whitaker HC; Heavey S
Sci Rep; 2020 Sep; 10(1):14380. PubMed ID: 32873828
[TBL] [Abstract][Full Text] [Related]
3. Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1.
Cen B; Mahajan S; Wang W; Kraft AS
Cancer Res; 2013 Jun; 73(11):3402-11. PubMed ID: 23585456
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes.
Mumenthaler SM; Ng PY; Hodge A; Bearss D; Berk G; Kanekal S; Redkar S; Taverna P; Agus DB; Jain A
Mol Cancer Ther; 2009 Oct; 8(10):2882-93. PubMed ID: 19825806
[TBL] [Abstract][Full Text] [Related]
5. Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma.
Schatz JH; Oricchio E; Wolfe AL; Jiang M; Linkov I; Maragulia J; Shi W; Zhang Z; Rajasekhar VK; Pagano NC; Porco JA; Teruya-Feldstein J; Rosen N; Zelenetz AD; Pelletier J; Wendel HG
J Exp Med; 2011 Aug; 208(9):1799-807. PubMed ID: 21859846
[TBL] [Abstract][Full Text] [Related]
6. eIF4B is a convergent target and critical effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in Abl transformants.
Chen K; Yang J; Li J; Wang X; Chen Y; Huang S; Chen JL
Oncotarget; 2016 Mar; 7(9):10073-89. PubMed ID: 26848623
[TBL] [Abstract][Full Text] [Related]
7. PIM activity in tumours: A key node of therapy resistance.
Rebello RJ; Huglo AV; Furic L
Adv Biol Regul; 2018 Jan; 67():163-169. PubMed ID: 29111105
[TBL] [Abstract][Full Text] [Related]
8. PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways.
Meja K; Stengel C; Sellar R; Huszar D; Davies BR; Gale RE; Linch DC; Khwaja A
Br J Haematol; 2014 Oct; 167(1):69-79. PubMed ID: 24975213
[TBL] [Abstract][Full Text] [Related]
9. Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer.
Malone T; Schäfer L; Simon N; Heavey S; Cuffe S; Finn S; Moore G; Gately K
Pharmacol Ther; 2020 Mar; 207():107454. PubMed ID: 31836451
[TBL] [Abstract][Full Text] [Related]
10. PIM1 targeted degradation prevents the emergence of chemoresistance in prostate cancer.
Torres-Ayuso P; Katerji M; Mehlich D; Lookingbill SA; Sabbasani VR; Liou H; Casillas AL; Chauhan SS; Serwa R; Rubin MR; Marusiak AA; Swenson RE; Warfel NA; Brognard J
Cell Chem Biol; 2024 Feb; 31(2):326-337.e11. PubMed ID: 38016478
[TBL] [Abstract][Full Text] [Related]
11. Rational cotargeting of Pim-1 and Akt in prostate cancer.
Toren P; Zoubeidi A
Expert Rev Anticancer Ther; 2013 Aug; 13(8):937-9. PubMed ID: 23984895
[TBL] [Abstract][Full Text] [Related]
12. PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis.
Lim JT; Singh N; Leuvano LA; Calvert VS; Petricoin EF; Teachey DT; Lock RB; Padi M; Kraft AS; Padi SKR
Mol Cancer Ther; 2020 Sep; 19(9):1809-1821. PubMed ID: 32753387
[TBL] [Abstract][Full Text] [Related]
13. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
Pungsrinont T; Kallenbach J; Baniahmad A
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
[TBL] [Abstract][Full Text] [Related]
14. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
[TBL] [Abstract][Full Text] [Related]
15. Cell-permeable carboxyl-terminal p27(Kip1) peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase.
Morishita D; Takami M; Yoshikawa S; Katayama R; Sato S; Kukimoto-Niino M; Umehara T; Shirouzu M; Sekimizu K; Yokoyama S; Fujita N
J Biol Chem; 2011 Jan; 286(4):2681-8. PubMed ID: 21062737
[TBL] [Abstract][Full Text] [Related]
16. The survival kinases Akt and Pim as potential pharmacological targets.
Amaravadi R; Thompson CB
J Clin Invest; 2005 Oct; 115(10):2618-24. PubMed ID: 16200194
[TBL] [Abstract][Full Text] [Related]
17. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
Kirschner AN; Wang J; van der Meer R; Anderson PD; Franco-Coronel OE; Kushner MH; Everett JH; Hameed O; Keeton EK; Ahdesmaki M; Grosskurth SE; Huszar D; Abdulkadir SA
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505253
[TBL] [Abstract][Full Text] [Related]
18. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
[TBL] [Abstract][Full Text] [Related]
19. PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance.
Holder SL; Abdulkadir SA
Curr Cancer Drug Targets; 2014; 14(2):105-14. PubMed ID: 24274399
[TBL] [Abstract][Full Text] [Related]
20. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
